You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Qlucore launches AI-based AML test
Login
Username:

Password:


Related Headlines

GSK reports strong early-stage data for B7-H4 ADC in gynaecological cancers

FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer

Almirall expands supercomputing and AI collaboration with Barcelona Supercomputing Center

Qlucore launches AI-based AML test

EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria

Haisco Pharmaceutical signs global pain‑drug licensing deal with AbbVie

AnBogen Therapeutics to present Imofinostat (ABT-301) breakthroughs at AACR 2026

Verastem Oncology presents two-year follow-up data on avutometinib and defactinib in recurrent low-grade serous ovarian cancer

DualityBio reports China NMPA acceptance of BLA for T-Pam for treatment of unresectable or metastatic HER2-positive breast cancer

Gan & Lee and JW Pharmaceutical sign licensing deal for Bofanglutide Injection in South Korea

Oricell Therapeutics completes USD110m pre-IPO financing

ArkBio completes first cohort dosing in Australian phase I trial of antiviral drug-Fc conjugate for influenza

Tempus expands oncology collaboration with Gilead to accelerate AI-driven R&D

Eli Lilly launches Foundayo weight‑loss pill in the US

AtaiBeckley reports rapid and durable Phase 2a responses to BPL‑003 in treatment‑resistant depression

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026